Mehdi Hamadani

"God created all diseases except GvHD, that we created" Hillard Lazarus
Transplanters carry guilt of poor patient outcomes and NRM.
The type of cGVHD 👇 reminds me why I vowed NEVER to use tac/mtx again. With ptCY & other data IMO it is no longer acceptable.
#GvHD #alloHCT

Answer: T-LGL clone. Often donor in origin
- Associated with neutropenia.
- Can be clonal
- rule out viral reactivations (EBV, CMV etc)
- I often treat (in neutropenics) 60mg pred x 10-14days [no taper]
In this patients, post pred the clonal T-LGL diappeared

❓Quiz ⏲️⏲️: 68yr old MDS patient day +167 post ptCY-based matched Allo HCT. No #GvHD
- On 0.5mg of tacrolimus
- CBC showed WBC of 2.0; platelets 204. ANC 600/uL
- On exam no adenopathy
- T-cell chimerism fully donor
- PB flow shown below
Diagnosis & Rx?? #bmtsm Allo 🦪

People wonder why physicians #burnout
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)

NFC north not doing well. Still licking my packer wounds, yet again

The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBC...

Current status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars @gulrayzahmed & @Taha_CancerDoc @MCWCancerCenter #lymsm www.tandfonline.com/doi/full/10....

Our @BMTCTN 1506 deep drive on FLT3 MRD and #alloHCT #AML @BloodJournal
-15% have micro-clones = worse RFS
-MRD+ relapse with WT or with clones persisting (can monitoring in tailor duration?)
-if u eradicate MRD, u r fine
-Some micro-clones survive and strike if gilt stops

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) result...

Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...

a green bay packers football player with the number 52 on his uniform ALT: a green bay packers football player with the number 52 on his uniform

Playoff clinched @packers #GoPackGo

Pink ODI for #breastcancer awareness 🇵🇰 vs. 🇿🇦 #GoPakGo @LubnaChaudhary1 🏏

Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis Key Points. Air pollution exposure is common, and may increase risk of developing blood clots.Greater long-term exposure to air pollution (i.e., PM2.5, NOx

Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Recently saw my city #Lahore (Pakistan) and nearby #NewDehli breaking air pollution records ashpublications.org/blood/articl...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma PURPOSEWe conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphom...

Love seeing the Nivo-AVD story in older patients grow in Frontline c Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... congrats @PallawiTorkaMD
Need effective tools is frail/unfit/super elderly #lymsm

Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study Key Points. Glofitamab shows a 47% overall response rate (27% CR, 20% PR) and manageable safety in heavily pretreated r/r LBCL patients.Increased LDH is th

Safety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm ashpublications.org/bloodadvance...

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a...

Impressive results of Dara vs. W&W in Smoldering #myeloma. Delay in progression; 📉mortality risk, favorable AE profile. ✅ Checks all the 📦📦 (just because HR SMM does not meet MM definition, doesn't mean it is not a PCD) congrats @vincentrk.bsky.social et al.
www.nejm.org/doi/full/10....

CD19.20 dual CAR in third or later line DLBCL being presented by @niravshahmd #ASH24

I can see the convention center #ASH24

First selfie of #ASH24 with none other than @medihumdani.bsky.social 🩸 We are on our way to San Diego from Milwaukee! @ash-hematology.bsky.social

Severe aplastic anemia. ASTCT guidelines 2024

www.astctjournal.org/article/S266...

Much awaited ECOG 4151 results out. IMO definitely ends debate for autoHCT in MCL in MRD negative CR1. #PracticeChaning and congrats to my friend @timfenske in advancing patient care @MCWCancerCenter @ASH_hematology #ASH2025
ash.confex.com/ash/2024/web...

a green bay packers player wearing a helmet with the letter c on it ALT: a green bay packers player wearing a helmet with the letter c on it

Go Pack Go @gbpackers.bsky.social

University of Bologna, oldest in the world and its iconic Anatomical Theatre

A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We

Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm ashpublications.org/bloodadvance...

@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea

Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/articl...

Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 - Capstan Therapeutics Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024

🚨Capstan Therapeutics Preclinical Data on In Vivo CAR-T
-engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's
-without need for lymphodepleting chemotherapy
-plans to clinic mid 2025
www.capstantx.com/posts/capsta...

Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM.
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24

🙏

a green background with a hand holding a flag and the words go go go ALT: a green background with a hand holding a flag and the words go go go

Packers aka Bear owners

WNDR Chicago